607 14th Street, NW, Suite 800 Washington, D.C. 20005
Tel: (202) 783-6040 Fax: (202) 783-6031 Email: jhynds@rfem.com Joseph A. Hynds
Mr. Hynds practices across the full spectrum of intellectual
property law, with a particular focus on patent infringement litigation. He has extensive experience with all aspects of patent litigation in U.S. district courts and before the U.S. International Trade Commission. He has handled cases covering a broad range of pharmaceutical, medical device, biotechnology, telecommunications, chemical, e-commerce and electrical technologies. He also has participated in numerous appeals to the U.S. Court of Appeals for the Federal Circuit. Mr. Hynds has particular expertise in Hatch-Waxman litigation and related issues.
Mr. Hynds also has substantial experience with patent
interference matters before the U.S. Patent and Trademark Office and
in the federal courts. He has represented clients in interference-rel
cal, mechanical and medical device technologies.
Mr. Hynds also counsels a variety of domestic and international clients on U.S.
intellectual property law, providing them with infringement, validity and enforceability opinions, and advises on licensing matters. He also assists clients in obtaining both U.S. and foreign patents to protect their intellectual property.
Mr. Hynds is currently an Adjunct Professor of Law at the George Washington University
Law School, where he teaches a course on “Practical Legal Writing.” (He takes an active role at the firm in mentoring summer associates.)
Mr. Hynds has been selected as a Washington DC Super Lawyer in the field of
Intellectual Property Litigation (2012-2013). He has been repeatedly named one of Washington DC’s Best Lawyers in Intellectual Property by Legal Times and was selected as a Best Lawyer for the Washington, DC section of The 2013 Best Lawyers in America® guide, in the fields of Litigation – Intellectual Property, Litigation – Patent, Patent Law, Trademark Law and Copyright Law. He is also listed in ALM’s 2010 Best Lawyers Annual Guide to Patent Law.
Mr. Hynds has been ranked in the IAM Patent 1000 (2013) for the DC Metro Area, he
was selected as a Washington DC Super Lawyer in the field of Intellectual Property Litigation (2012-2013). He has been repeatedly named one of Washington DC’s Best Lawyers in Intellectual Property by Legal Times and was selected as a Best Lawyer for the Washington, DC section of The 2013 Best Lawyers in America® guide, in the fields of Litigation – Intellectual Property, Litigation – Patent, Patent Law, Trademark Law and Copyright Law. He is also listed in ALM’s 2010 Best Lawyers Annual Guide to Patent Law.
He received his B.A. in Physics from Wabash College in 1986, and earned his J.D., with
honors, from George Washington University in 1991. Mr. Hynds was admitted to the Bar of the Commonwealth of Virginia in 1991 and to the District of Columbia Bar in 1993. He is registered to practice before the U.S. Patent and Trademark Office. He is a member of the American Bar Association (Patent Trademark & Copyright Law Section), and served as Chairman, Interference Subcommittee. He is also a member of the American Intellectual Property Law Association. From 1986 to 1989, Mr. Hynds was a patent examiner in the electrical arts at the U.S. Patent and Trademark Office.
Areas of Concentration:
Education:
George Washington University, J.D., with honors, 1991
Bar Admissions:
U.S. Court of Appeals for the Federal Circuit
U.S. District Court, District of Columbia
United States Patent and Trademark Office
Representative Litigation Matters: Federal District Court Eli Lilly & Co. v. Cobalt Laboratories, Civil Action No. 08-1550 (S.D. Ind.)
Pfizer Inc. v. Cobalt Laboratories, Inc. and Cobalt Pharmaceuticals, Inc., (D. Del) Sanofi Aventis v. Synthon Holdings BV, et al., (E.D.N.C.) KSI Inc. v. Unverferth, Inc. Civil Action No. 07-50075 (N.D. Ill.) Otsuka Pharm. v. Synthon Holdings BV, et al., (D.N.J.) Organon Inc. and Akzo Nobel N.V. v. Mylan Pharmaceuticals Inc., (D.N.J.) Investment Technologies Group, Inc. v. Liquidnet Holdings, Inc., Civil Action No. 07-510 (S.D.N.Y.) Illinois Tool Works v. Frito Lay, Civil Action No. 06-54 (D. Del.) Sepracor v. Breath, Civil Action No. 06-10043(D. Mass.) AIDS Healthcare Foundation v. GlaxoSmithKline, PLC Civil Action No. 03-2792 (C.D. Cal.) Paratek Microwave, Inc. v. Agile Materials and Techs., Inc. Civil Action No. 05-4121 (C.D. Cal.) Bristol-Meyer Squibb v. Mylan Pharm., Inc., Teva Pharm. USA, Inc., Barr Labs. et al., (S.D.N.Y.) Mylan Laboratories, Inc. v. Tommy G. Thompson Civil Action No. 04-1049 (D.D.C.) Guardian Industries Corp. Inc. v. AFG Industries, Inc. Civil Action No. 03-73722 (E.D. Mich.) Alza Corp. v. Mylan Laboratories, Inc. Civil Action No. 02-20 (D. Vt.) Ion Beam Applications v. The Titan Corporation Civil Action No. 00-1994 (S.D. Cal.) Schering Corp. v. Mylan Pharmaceuticals, Inc. Civil Action No. 00-1657 (D.N.J) Brassica v. Sproutman Civil Action No. 00-2951 (D. Md.) Mylan Pharmaceuticals Inc. v. Donna Shalala Civil Action No. 99-02995 (D.D.C.) Bayer and Pfizer v. Mylan Pharmaceuticals, Inc. Civil Action No. 97-1309 (W. D. Pa.) Key Pharmaceuticals (Schering) v. Mylan Pharmaceuticals, Inc. Civil Action No. 97-1462 (W.D. Pa.) Schering and Roussel UCLAF v. Zeneca Civil Action No. 95-566 (D. Del.) SmithKline Beecham v. Mylan Pharmaceuticals, Inc. Civil Action No. 94-2874 (E.D. Pa.) Burroughs Wellcome v. SmithKline Beecham, Civil Action No. 94-118 (E.D.N.C.) Nova Biomedical Corp. v. Mallinckrodt Sensor Systems, Inc. Civil Action No. 94-12288 (D. Mass.) Burroughs Wellcome v. Barr Labs and Novopharm, Ltd., Civil Action No. 91-41 (E.D.N.C.) Bayer Healthcare Pharmaceuticals inc. v. Watson Pharmaceuticals Inc. et al., Civil Action No. 01472 (D Nev.) International Trade Commission
In The Matter of Certain Plastic Containers, Investigation No. 337- TA-514 In The Matter of Certain Diltiazem Hydrochloride and Diltiazem Preparations, Investigation No. 337-TA-349 Patent Interference Proceedings Before the U.S. Patent and Trademark Office
Schwartz v. Sawney, Interference No. 105,317 Jurgovan v. Ramsey, Interference No. 105,173 Barker v. Elson, Interference No. 103,146 Wallace v. Landegren, Interference Nos. 103,419, 103,420 and 103,421 Anderson v. Selden v. Morgan, Interference No. 103,708 Kaufman v. Levinson, Interference No. 103,086 Arbitration Proceedings Before the American Arbitration Association
www.bfr.bund.de Relevance of EHEC O104:H4 in fenugreek seeds which are processed into other foods than sprouts and germ buds Updated Opinion No. 031/2011 of BfR of 26 July 2011 The BfR updated its Opinion No. 025/2011 of 11 July 2011 as to considerably emphasize the characteristics when using dry heat only for the elimination of EHEC on fenugreek seeds. There is a high probability
DRUG–EXCIPIENT INTERACTIONS Drug–Excipient Interactions Although considered pharmacologically inert, excipients can initiate, propagate or participate in chemical or physical interactions with drug compounds, which may compromise the effectiveness of a medication. Excipients may also contain impurities or form degradation products that in turn cause decomposition of drug substances.